Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL

CD19-targeted chimeric antigen receptor-modified T (CD19 CAR-T) cell therapy has been demonstrated as one of the most promising therapeutic strategies for treating B cell malignancies. However, it has shown limited treatment efficacy for diffuse large B cell lymphoma (DLBCL). This is, in part, due t...

Full description

Bibliographic Details
Main Authors: Wenping Zhou, Jinxin Miao, Zhenguo Cheng, Zhimin Wang, Jianyao Wang, Haoran Guo, Pengju Wang, Shuangshuang Lu, Lingling Si, Zhongxian Zhang, Louisa Chard Dunmall, Yanyan Liu, Nicholas R. Lemoine, Yaohe Wang
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
CAR-T cells
DLBCL
ODD
IL-12
Syrian hamster model
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770523000608

Internet

http://www.sciencedirect.com/science/article/pii/S2372770523000608

Similar Items